Skip to Content
Morningstar

WisdomTree BioRevolution ETF WDNA

Morningstar Medalist Rating
Medalist Rating as of | See WisdomTree Investment Hub

Morningstar’s Analysis WDNA

Will WDNA outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

  • Process Pillar

    The Process Pillar is our assessment of how sensible, clearly defined, and repeatable WDNA’s performance objective and investment process is for both security selection and portfolio construction.

  • People Pillar

    The People Pillar is our evaluation of the WDNA management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.

  • Parent Pillar

    The Parent Pillar is our rating of WDNA’s parent organization’s priorities and whether they’re in line with investors’ interests.

WisdomTree BioRevolution ETF’s management team is rated Average, but a solid investment process still helps this strategy retain its Morningstar Medalist Rating of Bronze.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a cost advantage over competitors, priced within the cheapest fee quintile among peers.

by Morningstar Manager Research
Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings WDNA

More WDNA Holdings
  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 25.2
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Twist Bioscience Corp

3.88 90,720
Healthcare

Novonesis AS Class B

2.92 68,263
Basic Materials

Blueprint Medicines Corp

2.80 65,418
Healthcare

Natera Inc

2.60 60,732
Healthcare

Geron Corp

2.57 60,011
Healthcare

Eli Lilly and Co

2.54 59,275
Healthcare

Agios Pharmaceuticals Inc

2.28 53,197
Healthcare

Vericel Corp

2.00 46,751
Healthcare

Sarepta Therapeutics Inc

1.95 45,627
Healthcare

Vertex Pharmaceuticals Inc

1.63 38,093
Healthcare